Details of the Drug Combination

General Information of Drug Combination (ID: DCPQ3TA)

Drug Combination Name
Indocyanine green Aflibercept
Indication
Disease Entry Status REF
Polypoidal Choroidal Vasculopathy Phase 1 [1]
Component Drugs Indocyanine green   DM2NQUY Aflibercept   DMT3D5I
Small molecular drug N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Indocyanine green
Disease Entry ICD 11 Status REF
Gastrointestinal disease DE2Z Approved [2]
Indocyanine green Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Indication(s) of Aflibercept
Disease Entry ICD 11 Status REF
Central retinal vein occlusion with macular edema N.A. Approved [3]
Diabetic macular edema 9B71.02 Approved [4]
Exudative age-related macular degeneration 9B78.3Z Approved [5]
Metastasis from malignant tumor of colon N.A. Approved [6]
Metastatic colorectal cancer 2B91 Approved [7]
Aflibercept Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Modulator [7]
Vascular endothelial growth factor B (VEGFB) TTPJQHE VEGFB_HUMAN Modulator [7]
Placenta growth factor (PlGF) TT48I1Y PLGF_HUMAN Modulator [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02597855) Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4844).
3 A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol. 2021 Oct-Dec;65(4):315-329.
4 Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Int J Mol Sci. 2022 Aug 20;23(16):9424.
5 Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR : A Randomized Controlled Trial. Adv Ther. 2020 Mar;37(3):1173-1187.
6 A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. Clin Oncol (R Coll Radiol). 2022 Aug;34(8):e323-e328.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
8 Primovist, Eovist: what to expect? J Hepatol. 2012 Aug;57(2):421-9.